Breast cancer is a kind of sex hormone-dependent disease. Factors that contribute to the international variation in incidence rates largely stem from the availability of early-detection services as well as differences in reproductive and hormonal factors, namely, risk factors associated with the level and duration of exposure to estrogen ([@bib33]). Based on several large clinical trials, estrogen blockade agents and several aromatase inhibitors (AIs) have become the standard adjuvant treatment for postmenopausal patients with endocrine-responsive early-breast cancer ([@bib9]; [@bib4]; [@bib17]; [@bib7]). In the past two decades, medical castration with luteinising hormone-releasing hormone agonists (LHRHa\'s) has been proposed in clinical practice. A frequently used LHRHa, goserelin, acts on the hypothalamic--pituitary axis and achieves reversible ovarian function suppression through receptor downregulation, and reduces luteinising hormone and estradiol to postmenopausal levels ([@bib15]; [@bib32]). Results from randomised clinical trials illustrated that the use of LHRHa did improve the survival duration of patients with hormone receptor-positive (estrogen receptor-positive (ER^+^) and/or progesterone receptor-positive (PR^+^)) breast cancers ([@bib31]; [@bib2]; [@bib10]). To elaborate the role of suppression of ovarian function in premenopausal patients with endocrine-responsive breast cancer more clearly, three trials were sponsored by the International Breast Cancer Study Group and coordinators. The results of SOFT/TEXT/PERCHE trials are awaited to answer these questions: the role of OFS, the role of AI in combination with OFS, and the role of chemotherapy in addition to endocrine therapies ([@bib29]).

As a kind of endocrine therapy, OFS can suppress breast cancer and improve the survival of premenopausal patients directly. Besides, OFS may also improve the survival of premenopausal patients with hormone receptor-positive breast cancer indirectly by decreasing the contralateral breast density (BD), endometrial thickness (ET), and so on. An initial BIG 1-98 study reported that postmenopausal breast cancer patients who received TAM had an increased incidence of thromboembolic events and endometrial cancer, although TAM had the predominant benefit on disease-free survival (DFS) and overall survival (OS), with a proportional reduction in contralateral breast cancer ([@bib3]; [@bib8]). The result of a subgroup analysis of the IBIS I Breast Cancer Prevention Trial showed that the discontinuation rate in the TAM group was high and occurred early because of gynaecological findings, most notable of which was the finding that in postmenopausal women, the median ET was significantly increased within 5 years in the TAM group ([@bib28]). In contrast, goserelin was not associated with any significant thromboembolic events or with the occurrence of endometrial cancer ([@bib5]). Intriguingly, goserelin significantly decreased the mammographic BD in patients carrying a *BRCA1* mutation, suggesting that goserelin may repress breast cancer recurrence by reducing mammary density. It was also confirmed that the reduction in BD apparently reduced the risk of contralateral breast cancer ([@bib11]).

Therefore, in this study, we hypothesised that the combination of goserelin with TAM could lead to downregulation of the estradiol level, resulting in reduced BD and ET, and ultimately leading to better DFS and OS in premenopausal and perimenopausal patients with hormone receptor-positive breast cancer. Thus, we initiated a randomised controlled trial that was sponsored by the Zhejiang Cancer Hospital in 2008 to validate our hypothesis.

Patients and Methods
====================

Participants and study design
-----------------------------

In this study, we recruited 110 premenopausal or perimenopausal women with hormone receptor-positive early-stage breast cancers who had undergone radical mastectomy or breast-conserving surgery at the Zhejiang Cancer Hospital in Hangzhou, China, between 22 June 2008 and 31 December 2009. Hormone receptor-positive means ER^+^ and/or PR^+^. The patients were randomly assigned to one of the two groups: the goserelin plus TAM group (*n*=56) or the TAM-alone group (*n*=54). Before receiving any endocrine therapy, these patients underwent surgery, followed by various radiochemotherapy regimens ([Table 1](#tbl1){ref-type="table"}) after evaluation by a multidisciplinary team consisting of a medical oncologist, radiation oncologist, and oncological surgeon. The data on the patients\' hormone receptor status and pathological diagnoses were obtained from the Department of Pathology, and clinical data were obtained from medical records. The Ethics Committee and the Academic Committee of Zhejiang Cancer Hospital approved this clinical study. Written informed consent was obtained from all patients for our study before trial entry. Both TAM (Nolvadex) and goserelin (Zoladex) were supplied by Astra-Zeneca China Co, Ltd (Shanghai, China). This study is registered, number NCT00827307.

Inclusion and exclusion criteria
--------------------------------

Patients with hormone receptor-positive early-stage breast cancers were included in the trial if there was no clinical evidence of metastatic or recurrent diseases, and if they were histopathologically confirmed as having stage-I/II ER^+^ and/or PR^+^-invasive breast cancer. The standard of hormone receptor-positive was ER ⩾10% and/or PR ⩾10% by immunohistochemistry stain. All patients were then characterised as premenopausal or perimenopausal (last menstruation \<6 months before trial entry) according to the National Comprehensive Cancer Network guidelines. Temporary chemotherapy-induced amenorrhea was allowed, provided that the premenopausal status was confirmed by estradiol level within 8 months before the final dose of chemotherapy. These patients were also required to be tested to ensure that they had adequate haematological reserves, renal function, and liver function.

The exclusion criteria were as follows: women with a life-threatening concurrent disease were excluded from the study. Pregnant and lactating women with early-stage breast cancer and patients with distant metastasis were ineligible for this study. Patients who had had intermissions of 8 weeks or longer from the time of surgery to postoperative chemotherapy, or from chemotherapy completion to study recruitment, were rejected according to the clinical protocol. In addition, those who had a history of previous endocrine treatment, bilateral ovarian radiation or excision, a malignant tumour in the past 5 years, and/or an allergy to goserelin or TAM were excluded from our study.

Patients were randomised after enrolment into this study. Treatment allocation was based on the permuted block technique. The voluntary aspect of the study was stressed, and confidentiality was guaranteed. All parameters of the two groups were comparable.

Intervention
------------

Patients were randomly assigned to receive either 20 mg of TAM alone (1 × 10-mg tablet orally twice daily) or 20 mg of TAM (1 × 10-mg tablet orally twice daily) plus 3.6 mg of goserelin (subcutaneous injection every 28 days). The treatment duration was 1.5 years, and treatment would be continued in the adjuvant setting for both treatment groups for at least 5 years. The adverse effects of the endocrine drugs were documented, and compliance was assessed with an interview at each follow-up visit. According to the adverse effect criteria of the Eastern Cooperative Oncology Group (ECOG), intermittent endocrine treatment was optional if a patient presented with life-threatening adverse effects.

Follow-up and outcome measures
------------------------------

All baseline data were collected before endocrine treatment. Blood levels of sex hormones (estradiol, progesterone, and human chorionic gonadotropin) and lipids (triglycerides, cholesterol, low-density lipoprotein, and high-density lipoprotein), and ultrasonic gynaecological examinations were performed at 3, 6, 12, and 18 months after initiating endocrine treatment. The minimum detectable value of estradiol by ELISA was 1.0 pg ml^−1^, with a sensitivity of 99%. Patients underwent contralateral mammography at 12 and 18 months after endocrine treatment initiation. Routine haematologic and clinical chemistry measurements were performed at every follow-up visit.

The primary end point was estradiol level, mammographic BD, ultrasonic ET, and blood lipid levels. Blood lipid and sex hormone levels were measured in the clinical laboratory, which is the central laboratory of Zhejiang province. Mammographic images performed in our hospital were all digitalised, and BD was quantitatively measured on craniocaudal images of the unaffected breast with the use of R2 quantra (Hologic Inc, Bedford, MA, USA) by a single radiologist. ET was measured by a specified sonologist.

Statistical analysis
--------------------

The estimated sample size was 48 in each group. To allow for 10% patient ineligibility, we set the sample size of our study at 110. Data analysis was carried out by using the SPSS 17.0 software (SPSS, Chicago, IL, USA). The quantified baseline data recorded in our study were compared between the two groups by using the Student\'s *t*-test, and qualified data were compared by the Fisher\'s exact test. The means of repeated measures were compared using a general linear model. *P*\<0.05 was considered statistically significant. All *P-*values were two-sided.

Results
=======

Characteristics of patients
---------------------------

In this study, we recruited 110 patients with early-stage hormone receptor-positive breast cancer to receive goserelin and TAM or TAM-alone therapy. Of these patients, 7 (6.36%, 5 in goserelin plus TAM group and 2 in TAM-alone group) declined to participate after the randomised assignment, resulting in continued administration of goserelin plus TAM or TAM alone in 103 women (51 in goserelin plus TAM group and 52 in TAM-alone group) ([Figure 1](#fig1){ref-type="fig"}). Moreover, one in TAM-alone group did not completely finish the assigned intervention. The median duration of follow-up was 3 years. In both groups of patients, the median ages at the time of diagnosis and at the time of menarche were 42 and 15 years, respectively. The body mass index was similar between these two groups (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}). Baseline data of the end point events, including BD, ET, and blood lipid levels, were not significantly different (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}). Baseline data of blood sex hormone levels in premenopausal and perimenopausal women indicated that the ovarian function of women in group A was comparable to that in group B (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}).

Adverse effects and recurrent events
------------------------------------

In this study, serious adverse effects were not observed during the period of intervention and follow-up. To date, all patients were alive and two had local recurrences.

Multivariance analysis of the end point events
----------------------------------------------

A statistical Mauchly\'s test was performed to validate the sphericity symmetry hypothesis for all measures, including estradiol, BD, ET, and blood lipid levels, but the results were negative (*P*\<0.05). Thus, the Greenhouse--Geisser multivariance analysis was used to compare the repeated measures, and the results are shown in [Table 2](#tbl2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}. As expected, estradiol levels were remarkably repressed in goserelin plus TAM group relative to TAM-alone group (F=9.949; *P*=0.002), whereas blood lipid levels were not apparently altered after addition of goserelin (*P*\>0.05). Compared with the use of TAM alone, the addition of goserelin to TAM significantly decreased BD (F=6.172; *P*=0.015). In parallel, the endometrium of patients assigned to receive goserelin plus TAM was clearly thinner compared with that of patients who received TAM-alone treatment (F=22.671; *P*\<0.001).

Moreover, a time-dependent trend was detected in the variation of BD according to a within-subject variance analysis (F=90.371; *P*\<0.001), whereas interactive effects between timing and groups were not observed (F=0.633; *P*=0.483). The multivariate analysis showed that after the 12-month follow-up, BD was significantly attenuated in the goserelin plus TAM group compared with the TAM-alone group (*P*\<0.05, [Table 3](#tbl3){ref-type="table"}). Bonferroni statistical data showed that after the 18-month follow-up, ET in the TAM-alone group was thicker than ET in the baseline data (mean difference =--0.751; *P*\<0.001). There was no significant difference in ET in the goserelin plus TAM group among the various time points, although a downward trend was noted (mean difference =--0.301; *P*=0.057).

Discussion
==========

Adjuvant endocrine therapy, which is an integral component in the treatment of patients with ER^+^ and/or PR^+^ breast cancer, exerts its effect by reducing the availability of estrogen to micrometastatic tumour cells ([@bib16]; [@bib3]; [@bib34]). Thus TAM, the most commonly used hormonal treatment for breast cancer patients, was introduced into clinical practice in the 1970s and has substantially improved survival duration in patients with hormone receptor-positive breast cancers ([@bib18]; [@bib27]; [@bib4]; [@bib6]; [@bib30]; [@bib24]). However, TAM is also able to produce notable estrogenic effects on the skeletal system, lipid metabolism, and various gynaecological tissues, including mammary gland, vaginal mucosa, and uterus ([@bib1]; [@bib30]; [@bib25]). Although TAM can improve survival duration in patients with estrogen-sensitive breast cancer, its long-term use inevitably increases the risk of adverse effects, such as endometrial cancer and disorders of lipid metabolism ([@bib14]; [@bib26]; [@bib35]). Routine screening of women without symptoms who are taking TAM has been suggested; however, this would not be cost-effective and would not likely lower mortality ([@bib1]; [@bib28]). Thus, an alternative strategy to address TAM-induced adverse effects and symptoms is to render the gynaecological tissues incapable of responding to estrogenic stimulation by using a LHRHa, such as goserelin ([@bib32]). Results from recent clinical trials support the clinical benefit of LHRHa\'s in terms of DFS and/or OS ([@bib21]; [@bib20]; [@bib26]; [@bib22]; [@bib5]; [@bib13]; [@bib12]), whereas [@bib15] pointed out in the Cochrane system review that there were insufficient data to compare the combinations of LHRHa\'s plus TAM with TAM alone. Thus, in this study, we designed a randomised controlled trial to compare the effects of combined goserelin plus TAM with TAM alone on estradiol, BD, ET, and lipids in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer.

We found that there was a significant difference in trends of estradiol levels between these two groups of patients after endocrine therapy. The average estradiol level in the TAM-alone group reached a summit within the first 3 months, which may have been caused by the accumulation of estrogen related to TAM, and then decreased by degrees and ultimately tended to stabilise at a high level. In contrast, the average estradiol level in the goserelin plus TAM group remained low and stable. Obviously, goserelin reduced the estradiol level when added to the TAM treatment.

Moreover, variation tendencies of BD and ET were statistically different between the two groups of patients after endocrine therapy. In both groups, a trend in descending BD was noted, but the average BD value in the goserelin plus TAM group was lower than that in the TAM-alone group. Breast density in the goserelin plus TAM group decreased more than in the TAM-alone group, indicating that TAM-induced BD reduction was enhanced by goserelin. Moreover, TAM-induced endometrial thickening was efficiently blocked by the addition of goserelin into the endocrine regimen. The average amount of ET was lower and was more stable in the goserelin plus TAM group than in the TAM-only group, where the average ET tended to increase. These data indicate that the effects of goserelin on ET and BD were due to goserelin-induced estradiol changes, which in turn prevented hyperplasia of mammary ductal, glandular, and endometrial epithelia.

Furthermore, our current study showed that goserelin did not seem to affect lipid metabolism in the study patients, which was supported by similar blood lipid levels observed in patients from both the goserelin plus TAM group and the TAM-alone group. After a 3-year follow-up, all patients were alive and there were only two recurrent events. Although the effect of combined goserelin and TAM on DFS and OS in premenopausal patients with stages I and II breast cancer was significantly validated by the Austrian Breast and Colorectal Cancer Study Group Trial 5 ([@bib19]), we were unable to determine conclusively whether better DFS and OS were reached because of the small sample size and short follow-up time of our study. However, our outcomes still partially reflected the great effects of goserelin on estradiol level, mammography BD, and ET against TAM in premenopausal and perimenopausal women with hormone receptor-positive breast cancer. A Korean study showed that mammography BD change during short-term use of adjuvant endocrine therapy was a significant predictor of long-term recurrence in women with ER^+^ breast cancer ([@bib23]). We speculate that goserelin combined with TAM may lead to better DFS and OS in premenopausal and perimenopausal women with hormone receptor-positive early-stage breast cancer than would be seen with the use of TAM alone through downregulation of estrogen and reduction of BD and ET. Further follow-up for this study is still continuing. However, a randomised trial with a larger sample size and longer duration of follow-up is subsequently needed to confirm these results.
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![**Variation trends of breast density, endometrial thickness, estradiol (E2), and lipidemia.** Note: Group (A), geserelin plus tamoxifen; group (B), tamoxifen alone. (A), E2; (B), breast density; (C), endometrial thickness; (D), triglycerides (TG); (E), Chol, cholesterol; (F), low-density lipoprotein (LDL); (G), high-density lipoprotein (HDL).](bjc2013324f2){#fig2}

###### Baseline clinical data

                                 **Group**                           
  ---------------------------- -------------- ------------- -------- -------------
  Age (year)                     42.41±5.24    42.52±5.22    −0.108      0.914
  Age at menarche (year)         15.18±1.43    15.31±1.45    −0.496      0.621
  BMI                            21.96±2.80    22.58±2.75    −1.142      0.256
  TG (mmol l^−1^)                2.29±1.22      1.91±1.18    1.638       0.105
  Chol (mmol l^−1^)              4.65±1.11      4.72±1.88    −0.231      0.818
  LDL (mmol l^−1^)               2.72±0.84      2.69±0.69    0.213       0.832
  HDL (mmol l^−1^)               1.43±0.70      1.35±0.50    0.709       0.480
  E2 (pg ml^−1^)                41.83±108.88   52.38±95.85   −0.522      0.603
  PRG (ng ml^−1^)                0.55±0.55      1.22±2.56    3.362       0.070
  HCG (mIU ml^−1^)               1.20±0.98      1.47±0.84    −1.513      0.133
  LH (IU l^−1^)                 13.07±11.58    18.26±16.67   −1.832      0.070
  FSH (mIU ml^−1^)              20.55±16.33    28.63±24.38   −1.972      0.051
  Endometrial thickness (cm)     3.77±1.07      4.04±1.20    −1.207      0.230
  Breast density (%)            51.24±13.66    56.44±14.11   −1.903      0.060
  Tumour size (cm)               2.87±1.15      2.32±1.21    2.424    **0.017**\*
  Number of involved node        2.41±3.31      1.15±3.31    2.052    **0.043**\*
  Histological grade                                         4.859       0.176
  Unspecified                   17 (30.36%)    8 (14.81%)                   
  1                              4 (7.14%)     8 (14.81%)                   
  2                             30 (53.57%)    34 (62.97%)                  
  3                              5 (8.93%)      4 (7.41)                    
  ER                                                         1.527       0.703
  −                              3 (5.36%)      5 (9.26%)                   
  \+                            13 (23.21%)    11 (20.37%)                  
  ++                            22 (39.29%)    17 (31.48%)                  
  +++                           18 (32.14%)    21 (38.89%)                  
  PR                                                         5.157       0.161
  −                              7 (12.50%)    9 (16.67%)                   
  \+                             6 (10.71%)    12 (22.22%)                  
  ++                            22 (39.29%)    12 (22.22%)                  
  +++                           21 (37.50%)    21 (38.89%)                  
  Surgical procedure                                         5.338       0.099
  Modified radical surgery      49 (87.50%)    52 (96.30%)                  
  Breast-conserving surgery      6 (10.71%)     1 (1.85%)                   
  Radical excision                 0 (0%)       1 (1.85%)                   
  Lumpectomy                     1 (1.79%)       0 (0%)                     
  Chemotherapy regimen                                       5.777       0.099
  No                             7 (12.50%)    6 (11.11%)                   
  TEC/TE                        36 (64.29%)    24 (44.44%)                  
  CEF                           12 (21.42%)    22 (40.74%)                  
  CEF-T/CE-T                     1 (1.79%)      2 (3.71%)                   
  Adjuvant chemotherapy                                      0.051       0.822
  No                             7 (12.50%)    6 (11.11%)                   
  Yes                           49 (87.50%)    48 (88.89%)                  
  Adjuvant radiotherapy                                      3.609       0.082
  Yes                           19 (33.93%)    28 (51.85%)                  
  No                            37 (66.07%)    26 (48.15%)                  

Abbreviations: BMI=body mass index; Chol=cholesterol; E2=estradiol; ER=estrogen receptor-positive; FSH=follicle-stimulating hormone; HCG=human chorionic gonadotropin; HDL=high-density lipoprotein; LDL=low-density lipoprotein; LH=luteinising hormone; PR=progesterone receptor-positive; PRG=progesterone; TAM=tamoxifen; TG=triglyceride. \**P*\<0.05.

###### Multivariate analysis of the repeated measures

  **Measure**             **Source**     ***F*-value**  ***P*-value**
  ----------------------- ------------- --------------- ---------------
  E2                      Time               2.884      **0.038**\*\*
                          Time\*group        1.735      0.162
                          Group              9.949      **0.002**\*
  Breast density (%)      Time              90.371      \<**0.001**
                          Time\*group        0.633      0.483
                          Group              6.172      **0.015**\*\*
  Endometrial thickness   Time               2.071      0.122
                          Time\*group       12.521      \<**0.001**
                          Group             22.671      \<**0.001**
  TG                      Time               1.091      0.353
                          Time\*group        1.671      0.173
                          Group              0.845      0.360
  Chol                    Time               0.129      0.911
                          Time\*group        0.540      0.616
                          Group              0.463      0.498
  LDL                     Time               0.420      0.758
                          Time\*group        1.578      0.190
                          Group              0.115      0.736
  HDL                     Time               1.262      0.287
                          Time\*group        1.013      0.388
                          Group              0.032      0.857

Abbreviations: Chol=cholesterol; E2=estradiol; HDL=high-density lipoprotein; LDL=low-density lipoprotein; TG=triglyceride.

Note: *Time* and *time*\**group* showed within-subject effects. *Group* showed between-subject effects. \**P*\<0.01. \*\**P*\<0.05.

###### Comparison of breast density between these two groups at various points of time

               **Mean±s.d.**                        
  ----------- --------------- ------------- ------- -------------
  Baseline      51.24±13.66    56.37±14.24   3.457      0.066
  12 Months     44.14±11.66    50.69±14.27   6.443   **0.013**\*
  18 Months     37.86±12.44    44.75±14.90   6.414   **0.013**\*

Abbreviation: TAM=tamoxifen. \**P*\<0.05
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